Uncategorized
Allergan reports 5% increase in Q1 net revenues
Allergan reported its first quarter 2017 continuing operations performance, including total net revenues of $3.6 billion, a 5% increase compared with the prior year quarter.The increase was driven by higher revenues in facial aesthetics, Botox Therapeutic, eye care products, Lo Loestrin, and the addition of LifeCell and new products including Vraylar and Viberzi, according to a news release from Allergan.